Literature DB >> 16905582

Targeting activated T cells: successful use of anti-CD25 monoclonal antibody basiliximab in a patient with systemic sclerosis.

H U Scherer, G-R Burmester, G Riemekasten.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16905582      PMCID： PMC1798302          DOI： 10.1136/ard.2005.046938

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  10 in total

Review 1.  Clinical advances in therapies targeting the interleukin-2 receptor.

Authors:  A C Church
Journal:  QJM       Date:  2003-02

2.  The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis.

Authors:  M Calguneri; S Apras; Z Ozbalkan; I Ertenli; S Kiraz; M A Ozturk; I Celik
Journal:  Clin Rheumatol       Date:  2003-10       Impact factor: 2.980

Review 3.  Non organ based laboratory markers in systemic sclerosis.

Authors:  N J McHugh; O Distler; R Giacomelli; G Riemekasten
Journal:  Clin Exp Rheumatol       Date:  2003       Impact factor: 4.473

4.  Oligoclonal T cell expansion in the skin of patients with systemic sclerosis.

Authors:  Lazaros I Sakkas; Bin Xu; Carol M Artlett; Song Lu; Sergio A Jimenez; Chris D Platsoucas
Journal:  J Immunol       Date:  2002-04-01       Impact factor: 5.422

5.  Soluble intercellular adhesion molecule-1 (sICAM-1) and soluble interleukin-2 receptors (sIL-2R) in scleroderma skin.

Authors:  K Søndergaard; K Stengaard-Pedersen; H Zachariae; L Heickendorff; M Deleuran; B Deleuran
Journal:  Br J Rheumatol       Date:  1998-03

6.  Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease.

Authors:  Ioannis Pakas; John P A Ioannidis; Katerina Malagari; Fotini N Skopouli; Haralampos M Moutsopoulos; Panayiotis G Vlachoyiannopoulos
Journal:  J Rheumatol       Date:  2002-02       Impact factor: 4.666

7.  Soluble interleukin-2 receptors in patients with systemic sclerosis. Clinical and laboratory correlations.

Authors:  D Degiannis; J R Seibold; M Czarnecki; J Raskova; K Raska
Journal:  Arthritis Rheum       Date:  1990-03

8.  Early T cell activation in the skin from patients with systemic sclerosis.

Authors:  A Kalogerou; E Gelou; S Mountantonakis; L Settas; E Zafiriou; L Sakkas
Journal:  Ann Rheum Dis       Date:  2005-08       Impact factor: 19.103

9.  Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis.

Authors:  Roberto Giacomelli; Gabriele Valentini; Felice Salsano; Paola Cipriani; Paola Sambo; Maria L Conforti; Antonietta Fulminis; Amalia De Luca; Giuseppina Farina; Marco Candela; Sergio Generini; Agostino De Francisci; Enrico Tirri; Michele Proietti; Stefano Bombardieri; Armando Gabrielli; Giorgio Tonietti; Marco M Cerinic
Journal:  J Rheumatol       Date:  2002-04       Impact factor: 4.666

10.  Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results.

Authors:  P Airò; E Danieli; G Parrinello; C M Antonioli; I Cavazzana; P Toniati; F Franceschini; R Cattaneo
Journal:  Clin Exp Rheumatol       Date:  2004 Sep-Oct       Impact factor: 4.473
  10 in total
  12 in total

1.  [Critical limb ischemia in systemic sclerosis].

Authors:  M O Becker; G Riemekasten
Journal:  Z Rheumatol       Date:  2012-06       Impact factor: 1.372

Review 2.  Immunotherapy of systemic sclerosis.

Authors:  Rebecca Manno; Francesco Boin
Journal:  Immunotherapy       Date:  2010-11       Impact factor: 4.196

Review 3.  [Clinical risk-adapted therapies in systemic sclerosis].

Authors:  G Riemekasten; D Dragun
Journal:  Z Rheumatol       Date:  2007-12       Impact factor: 1.372

Review 4.  [Therapy of systemic sclerosis].

Authors:  M Meurer; P Rehberger
Journal:  Hautarzt       Date:  2007-10       Impact factor: 0.751

Review 5.  Pharmacotherapy of systemic sclerosis.

Authors:  Arnold E Postlethwaite; L Jeff Harris; Syed H Raza; Swapna Kodura; Titilola Akhigbe
Journal:  Expert Opin Pharmacother       Date:  2010-04       Impact factor: 3.889

6.  Changes in peripheral CD4+CD25(high) regulatory T cells in the acute-on-chronic liver failure patients with plasma exchange treatment.

Authors:  Wei-lin Mao; Yu-Feng Lou; Bo Ye; Sha Lin; Yue-mei Chen; Yu Chen
Journal:  Inflammation       Date:  2012-04       Impact factor: 4.092

7.  [Towards an implementation of guidelines for the therapy of systemic sclerosis (scleroderma): between desire and reality].

Authors:  M O Becker; U Müller-Ladner; G Riemekasten
Journal:  Z Rheumatol       Date:  2010-06       Impact factor: 1.372

Review 8.  Immunosuppressive peptides and their therapeutic applications.

Authors:  Kathrin Thell; Roland Hellinger; Gernot Schabbauer; Christian W Gruber
Journal:  Drug Discov Today       Date:  2013-12-11       Impact factor: 7.851

9.  Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression.

Authors:  Timothy R D J Radstake; Lenny van Bon; Jasper Broen; Mark Wenink; Kim Santegoets; Yanhui Deng; Anila Hussaini; Robert Simms; William W Cruikshank; Robert Lafyatis
Journal:  PLoS One       Date:  2009-06-22       Impact factor: 3.240

10.  Systemic sclerosis: current concepts in pathogenesis and therapeutic aspects of dermatological manifestations.

Authors:  Vishalakshi Viswanath; Meghana M Phiske; Vinay V Gopalani
Journal:  Indian J Dermatol       Date:  2013-07       Impact factor: 1.494
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.